Choice of agents to limit the coagulation cascade in acute coronary syndromes
- Cite this article as:
- Becker, R.C. Curr Cardiol Rep (2002) 4: 272. doi:10.1007/s11886-002-0062-0
- 34 Downloads
Arterial thrombosis, the predominant event in acute coronary syndromes (ACS), is the end-result of endothelial cell dysfunction, impaired vascular thromboresistance, and sudden atheromatous plaque disruption, each occurring amid a backdrop of inflammation and inflammatory mediators. Because the contribution of individual coagulation proteins to coronary arterial thrombosis varies from modest to marked, selective pharmacologic targeting is both pathobiologically sound and clinically preferred. The development of secondgeneration anticoagulants with broadened therapeutic windows represents an advance in the management of ACS.
Unable to display preview. Download preview PDF.